Evidence map›Paper›PMID 24918823›Full record

ArticleBritish journal of cancer2014

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

M S Carlino, L E Haydu, H Kakavand, A M Menzies, A L Hamilton, B Yu, C C Ng, W A Cooper, J F Thompson, R F Kefford and 3 more

2 registry-linked trialsOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04911998 completednot on this mapstarted 2021, after this paper: background citation

A Prospective Non Interventional Study on Targeted Therapy for Patients With Unresectable or Metastatic BRAFV600E Mutant Melanoma

TypeobservationalSponsorPierre Fabre MedicamentRan2021 to 2024Enrolled400ConditionsMelanoma (Skin), Metastatic Melanoma, BRAF V600 Mutation
NCT05119829 unknown statusnot on this map

Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications

TypeobservationalSponsorHellenic Cooperative Oncology GroupRan1998 to 2023Enrolled80ConditionsMelanoma
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.Virchows Archiv : an international journal of pathology · 2024
    Article
  6. Article
  7. Article
  8. South Asian journal of cancer · 2023
    Article
  9. Pathogenic mutation hotspots in protein kinase domain structure.Protein science : a publication of the Protein Society · 2023
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

M S Carlino1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia [3] Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia [4] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
L E Haydu1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
H Kakavand1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
A M Menzies1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
A L Hamilton1] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia [2] Department of Medical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
B Yu1] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia [2] Department of Medical Genomics, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
C C NgDepartment of Medical Genomics, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
W A Cooper1] Department of Medical Genomics, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia [2] Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia [3] School of Medicine, University of Western Sydney, Sydney, NSW, Australia.
J F Thompson1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia [3] Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
R F Kefford1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia [3] Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia [4] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
S A O'Toole1] Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia [2] Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia [3] The Kinghorn Cancer Centre and Cancer Program Garvan Institute of Medical Research, Victoria Street, Darlinghurst, New South Wales, Australia.
R A Scolyer1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia [3] Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
G V Long1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Melanoma Institute Australia · AUUniversity of Sydney · AURoyal Prince Alfred Hospital · AUWestmead Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic significance of BRAF and NRAS mutations in metastatic melanoma patients remains uncertain, with several studies reporting conflicting results, often biased by the inclusion of patients treated with BRAF and MEK (MAPK) inhibitors. We therefore interrogated a historical cohort of patients free of the confounding influence of MAPK inhibitor therapy.

methodsPatients with available archival tissue first diagnosed with metastatic melanoma between 2002 and 2006 were analysed. Mutational analysis was performed using the OncoCarta Panel. Patient characteristics, treatment outcome and survival were correlated with BRAF/NRAS mutation status.

resultsIn 193 patients, 92 (48%) melanomas were BRAF-mutant, 39 (20%) were NRAS-mutant and 62 (32%) were wild-type for BRAF/NRAS mutations (wt). There was no difference in response to chemotherapy based on mutation status (35-37%). The distant disease-free interval (DDFI) was significantly shorter in patients with wt melanoma (27.9 months vs 35.1 for BRAF and 49.1 for NRAS) although this was not significant in multivariate analysis. Survival from stage IV melanoma diagnosis was not significantly different based on mutation status. The DDFI was significantly shorter in patients with BRAF(V600K/R) versus BRAF(V600E) melanoma in univariate and multivariate analyses.

conclusionsBRAF and NRAS mutation status does not influence survival in metastatic melanoma.

Indexed as

MutationAdolescentAdultAgedAged, 80 and overCohort StudiesDisease-Free SurvivalFemaleGTP PhosphohydrolasesHumansMaleMelanomaMembrane ProteinsMiddle AgedNeoplasm MetastasisPrognosisBRAF protein, humanGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID24918823
PMCPMC4102942
OpenAlexW2097025111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.